Inclusion Criteria:

- Performance status Karnofsky index ≥ 60%.

- Early stage as well as advanced/metastatic ovarian cancer proven by abdominal
ultrasonography, chest x-ray, Computerized axial tomography scan.

- Histologically: epithelial/germ cell

- Haematology: absolute neutrophil count: ≥2X10^9/L; Platelet: ≥150X10^9/L;
Haemoglobin: ≥ 10g/dL

- Liver function: total bilirubin: ≤1X UNL (upper normal limit); Aspartate transaminase
& Alanine aminotransferase: ≤2.5 x UNL; Alkaline phosphatase: ≤2.5 UNL

- Renal function: Creatinine: ≤130 µmol/L; If creatinine > 130 µmol/L, the 24 hour
creatinine clearance should be > 60 ml/min.

Exclusion Criteria:

- Symptomatic peripheral neuropathy > grade 1 by National Cancer Institute - Common
Toxicity Criteria scale

- Uncontrolled diabetes mellitus and uncontrolled hypertension

- Pregnant, or lactating patients(patients of childbearing potential must be using
adequate contraception).

- Active infection or other serious underlying medical condition not compatible with
program entry eg. congestive heart failure, previous myocardial infarction within 6
months prior to treatment.

The above information is not intended to contain all considerations relevant to a
patient's potential participation in a clinical trial.